首页> 外国专利> Antibodies against human csf-1r for use in induction of lymphocytosis in lymphomas or leukemias

Antibodies against human csf-1r for use in induction of lymphocytosis in lymphomas or leukemias

机译:抗人csf-1r抗体,用于诱导淋巴瘤或白血病中的淋巴细胞增多

摘要

Referring to an Antibody that binds csf-1r for use in Inducing leukemic Cell lymphocytosis in lymphomas or leukemias.Where the lymphocytosis, increases the percentage of circulating leukemic cells expressing CD19, CD20 and / or in the Peripheral Blood.Where the said Antibody comprises: (a) a variable domain of heavy chain of SEQ ID no: 23 VH and VL light chain variable domain of SEQ ID no: 24Or (b) a variable domain of heavy chain of SEQ ID no: 31 VH and VL light chain variable domain of SEQ ID no: 32(c) a variable domain of heavy chain of SEQ ID no: 39 VH and VL light chain variable domain of SEQ ID no: 40Or (d) a variable domain of heavy chain of SEQ ID no: 47 VH and VL light chain variable domain of SEQ ID no: 48E) or a variable domain of heavy chain of SEQ ID no: 55 VH and VL light chain variable domain of SEQ ID no: 56.It also relates to a combination Therapy of Antibodies that bind to Human csf-1r with Antibodies that bind to human CD20.
机译:涉及与csf-1r结合的抗体,用于在淋巴瘤或白血病中诱导白血病细胞淋巴细胞增多。在淋巴细胞增多的地方,增加表达CD19,CD20和/或外周血的循环白血病细胞的百分比。 :(a)SEQ ID NO:23 VH的重链可变域和SEQ ID NO:24 VL的轻链可变域或(b)SEQ ID NO:31 VH的重链可变域和VL轻链可变域SEQ ID No:32的结构域(c)SEQ ID No:39的重链可变域VH和SEQ ID No:40的VL轻链可变域或(d)SEQ ID No:47重链可变域(SEQ ID NO:48E的VH和VL轻链可变域)或SEQ ID NO:55的重链可变域.SEQ ID NO:56的VH和VL轻链可变域。它也涉及抗体的联合疗法通过与人CD20结合的抗体与人csf-1r结合。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号